Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
Søren S Lund, Lise Tarnow, Coen D A Stehouwer, Casper G Schalkwijk, Tom Teerlink, Jørgen Gram, Kaj Winther, Merete Frandsen, Ulla M Smidt, Oluf Pedersen, Hans-Henrik Parving, Allan A Vaag
Dive into the research topics of 'Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes'. Together they form a unique fingerprint.